루푸스 치료제 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 치료 유형별, 투여 경로별, 최종사용자별, 지역별 부문, 경쟁(2020-2030년)
Lupus Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment Type, By Route of Administration, By End User, By Region & Competition, 2020-2030F
상품코드:1771037
리서치사:TechSci Research
발행일:2025년 07월
페이지 정보:영문 180 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 루푸스 치료제 시장은 2024년에는 71억 2,000만 달러로 평가되며, 2030년에는 107억 4,000만 달러에 달하며, CAGR 7.09%로 성장할 것으로 예측됩니다.
이러한 성장은 신체의 면역체계가 자신의 조직과 장기를 공격하는 자가면역질환인 루푸스의 전 세계 유병률 증가에 크게 기인합니다. 이 질환은 염증을 유발하고 관절, 피부, 신장, 폐, 심장, 뇌 등 여러 장기에 영향을 미칩니다. 루푸스는 증상이 다양하고 다른 질환과 중복되는 경우가 많아 진단이 어려운 경우가 많습니다. 특징적인 증상으로 뺨 전체에 나비 모양의 발진이 나타나는 경우가 많습니다. 유전적 소인을 가진 사람도 있지만, 감염이나 약물, 햇빛에 노출되면 발병할 수 있습니다. 미국 루푸스 재단에 따르면 전 세계에서 500만 명 이상이 루푸스에 걸렸으며, 주요 연령대는 15세에서 44세 사이입니다.
시장 개요
예측 기간
2026-2030
시장 규모 : 2024년
71억 2,000만 달러
시장 규모 : 2030년
107억 4,000만 달러
CAGR : 2025-2030년
7.09%
급성장 부문
생물제제
최대 시장
북미
시장 성장 촉진요인
전신성 홍반성 루푸스(SLE)의 전 세계 유병률 상승
주요 시장 이슈
첨단 치료제의 고비용과 저소득 지역에서의 접근성 제한으로 인한 접근성 제한
주요 시장 동향
루푸스 치료에서 맞춤형 의료 도입 확대
목차
제1장 개요
제2장 조사 방법
제3장 개요
제4장 고객의 소리
제5장 COVID-19가 세계의 루푸스 치료제 시장에 미치는 영향
제6장 임상시험 분석
제7장 세계의 루푸스 치료제 시장 전망
시장 규모·예측
금액별
시장 점유율·예측
치료 유형별(NSAIDs, 코르티코스테로이드, 항말라리아약, 면역억제제, 생물제제, 기타)
투여 경로(경구, 정맥내, 피하)
최종사용자별(병원·진료소, 외래 진료 센터, 기타)
지역별
기업별(2024)
시장 맵
치료 유형별
투여 경로별
최종사용자별
지역별
제8장 북미의 루푸스 치료제 시장 전망
시장 규모·예측
시장 점유율·예측
북미 : 국가별 분석
미국
캐나다
멕시코
제9장 유럽의 루푸스 치료제 시장 전망
시장 규모·예측
시장 점유율·예측
유럽 : 국가별 분석
독일
프랑스
영국
스페인
이탈리아
제10장 아시아태평양의 루푸스 치료제 시장 전망
시장 규모·예측
시장 점유율·예측
아시아태평양 : 국가별 분석
중국
인도
일본
한국
호주
제11장 남미의 루푸스 치료제 시장 전망
시장 규모·예측
시장 점유율·예측
남미 : 국가별 분석
브라질
아르헨티나
콜롬비아
제12장 중동 및 아프리카의 루푸스 치료제 시장 전망
시장 규모·예측
시장 점유율·예측
중동 및 아프리카 : 국가별 분석
남아프리카공화국
사우디아라비아
아랍에미리트
제13장 시장 역학
촉진요인
과제
제14장 시장 동향과 발전
제품 출시
합병과 인수
최근 동향
제15장 세계의 루푸스 치료제 시장 : SWOT 분석
제16장 Porter's Five Forces 분석
업계내 경쟁
신규 참여의 가능성
공급업체의 힘
고객의 힘
대체품의 위협
제17장 경쟁 구도
GSK plc.
Novartis AG
AstraZeneca
F. Hoffmann-La Roche Ltd
Eli Lilly and Company
ImmuPharma PLC
Pfizer Inc.
Sanofi S.A.
Bristol-Myers Squibb Company
Merck & Co., Inc.
제18장 전략적 제안
제19장 조사회사 소개·면책사항
KSA
영문 목차
영문목차
The Global Lupus Therapeutics Market was valued at USD 7.12 billion in 2024 and is projected to reach USD 10.74 billion by 2030, growing at a CAGR of 7.09%. This growth is largely attributed to the increasing global prevalence of lupus, an autoimmune condition in which the body's immune system attacks its own tissues and organs. The disease causes inflammation that can affect multiple systems, including the joints, skin, kidneys, lungs, heart, and brain. Diagnosing lupus is often difficult due to its diverse and overlapping symptoms with other conditions. A signature symptom in many cases is a butterfly-shaped rash across the cheeks. While some individuals are genetically predisposed, lupus can also be triggered by infections, medications, or exposure to sunlight. According to the Lupus Foundation of America, over five million people worldwide are affected by lupus, primarily those aged 15 to 44.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 7.12 Billion
Market Size 2030
USD 10.74 Billion
CAGR 2025-2030
7.09%
Fastest Growing Segment
Biologics
Largest Market
North America
Key Market Drivers
Rising Global Prevalence of Systemic Lupus Erythematosus (SLE)
The growing prevalence of systemic lupus erythematosus (SLE), the most common and severe form of lupus, is a significant driver of the lupus therapeutics market. SLE is a chronic autoimmune condition where the immune system mistakenly attacks healthy tissues, resulting in inflammation and organ damage. This condition is especially prevalent among women of reproductive age and is disproportionately seen in African American, Hispanic, and Asian populations. The increasing awareness, improved diagnostic capabilities, and rising incidence of autoimmune disorders globally are collectively contributing to the market's expansion.
Key Market Challenges
High Cost of Advanced Therapies and Limited Access in Low-Income Regions
Despite advancements in treatment, the high cost of biologics and targeted lupus therapies presents a major challenge, particularly in low- and middle-income regions. These innovative drugs, although effective, are often unaffordable for many patients-even in high-income countries with insurance coverage. In regions with limited healthcare infrastructure and funding, access to these treatments remains restricted. The economic burden limits the use of advanced therapeutics, thereby widening the treatment gap. Additionally, constrained healthcare budgets and inadequate reimbursement policies further hinder the adoption of these high-cost medications.
Key Market Trends
Growing Adoption of Personalized Medicine in Lupus Treatment
An emerging trend in the lupus therapeutics market is the growing shift toward personalized medicine. This approach tailors treatment to an individual's genetic, molecular, and phenotypic characteristics. Personalized strategies are especially important in lupus, which is marked by variable symptoms, disease progression, and treatment responses.
Advances in genomics, proteomics, and immunophenotyping are enabling more precise patient stratification and treatment planning. For instance, researchers funded by the NIH have identified immune pathway signatures-such as type I interferon activity-that may help predict patient response to specific biologics. Clinical trials are now being designed with biomarker-driven enrollment to increase efficacy, reduce side effects, and streamline drug approvals.
These innovations are supported by government initiatives such as the FDA's Precision Medicine Initiative and the European Union's Horizon Europe framework, both of which prioritize the development of targeted therapies for complex diseases like lupus.
Key Market Players
GSK plc.
Novartis AG
AstraZeneca
F. Hoffmann-La Roche Ltd
Eli Lilly and Company
ImmuPharma PLC
Pfizer Inc.
Sanofi S.A.
Bristol-Myers Squibb Company
Merck & Co., Inc.
Report Scope:
In this report, the Global Lupus Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Lupus Therapeutics Market, By Treatment Type:
NSAIDs
Corticosteroids
Antimalarials
Immunosuppressants
Biologics
Others
Lupus Therapeutics Market, By Route of Administration:
Oral
Intravenous
Subcutaneous
Lupus Therapeutics Market, By End User:
Hospitals & Clinics
Ambulatory Care Centers
Others
Lupus Therapeutics Market, By Region:
North America
United States
Mexico
Canada
Europe
France
Germany
United Kingdom
Italy
Spain
Asia-Pacific
China
India
South Korea
Japan
Australia
South America
Brazil
Argentina
Colombia
Middle East and Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies presents in the Global Lupus Therapeutics Market.
Available Customizations:
Global Lupus Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Impact of COVID-19 on Global Lupus Therapeutics Market
6. Clinical Trial Analysis
6.1. Ongoing Clinical Trials
6.2. Completed Clinical Trials
6.3. Terminated Clinical Trials
6.4. Breakdown of Pipeline, By Development Phase
6.5. Breakdown of Pipeline, By Status
6.6. Breakdown of Pipeline, By Study Type
6.7. Breakdown of Pipeline, By Region
6.8. Clinical Trials Heat Map
7. Global Lupus Therapeutics Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Treatment Type (NSAIDs, Corticosteroids, Antimalarials, Immunosuppressants, Biologics, Others)
7.2.2. By Route of Administration (Oral, Intravenous, Subcutaneous)
7.2.3. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
7.2.4. By Region
7.2.5. By Company (2024)
7.3. Market Map
7.3.1. By Treatment Type
7.3.2. By Route of Administration
7.3.3. By End User
7.3.4. By Region
8. North America Lupus Therapeutics Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Treatment Type
8.2.2. By Route of Administration
8.2.3. By End User
8.2.4. By Country
8.3. North America: Country Analysis
8.3.1. United States Lupus Therapeutics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Treatment Type
8.3.1.2.2. By Route of Administration
8.3.1.2.3. By End User
8.3.2. Canada Lupus Therapeutics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Treatment Type
8.3.2.2.2. By Route of Administration
8.3.2.2.3. By End User
8.3.3. Mexico Lupus Therapeutics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Treatment Type
8.3.3.2.2. By Route of Administration
8.3.3.2.3. By End User
9. Europe Lupus Therapeutics Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Treatment Type
9.2.2. By Route of Administration
9.2.3. By End User
9.2.4. By Country
9.3. Europe: Country Analysis
9.3.1. Germany Lupus Therapeutics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Treatment Type
9.3.1.2.2. By Route of Administration
9.3.1.2.3. By End User
9.3.2. France Lupus Therapeutics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Treatment Type
9.3.2.2.2. By Route of Administration
9.3.2.2.3. By End User
9.3.3. United Kingdom Lupus Therapeutics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Treatment Type
9.3.3.2.2. By Route of Administration
9.3.3.2.3. By End User
9.3.4. Spain Lupus Therapeutics Market Outlook
9.3.4.1. Market Size & Forecast
9.3.4.1.1. By Value
9.3.4.2. Market Share & Forecast
9.3.4.2.1. By Treatment Type
9.3.4.2.2. By Route of Administration
9.3.4.2.3. By End User
9.3.5. Italy Lupus Therapeutics Market Outlook
9.3.5.1. Market Size & Forecast
9.3.5.1.1. By Value
9.3.5.2. Market Share & Forecast
9.3.5.2.1. By Treatment Type
9.3.5.2.2. By Route of Administration
9.3.5.2.3. By End User
10. Asia-Pacific Lupus Therapeutics Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Treatment Type
10.2.2. By Route of Administration
10.2.3. By End User
10.2.4. By Country
10.3. Asia-Pacific: Country Analysis
10.3.1. China Lupus Therapeutics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Treatment Type
10.3.1.2.2. By Route of Administration
10.3.1.2.3. By End User
10.3.2. India Lupus Therapeutics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Treatment Type
10.3.2.2.2. By Route of Administration
10.3.2.2.3. By End User
10.3.3. Japan Lupus Therapeutics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Treatment Type
10.3.3.2.2. By Route of Administration
10.3.3.2.3. By End User
10.3.4. South Korea Lupus Therapeutics Market Outlook
10.3.4.1. Market Size & Forecast
10.3.4.1.1. By Value
10.3.4.2. Market Share & Forecast
10.3.4.2.1. By Treatment Type
10.3.4.2.2. By Route of Administration
10.3.4.2.3. By End User
10.3.5. Australia Lupus Therapeutics Market Outlook
10.3.5.1. Market Size & Forecast
10.3.5.1.1. By Value
10.3.5.2. Market Share & Forecast
10.3.5.2.1. By Treatment Type
10.3.5.2.2. By Route of Administration
10.3.5.2.3. By End User
11. South America Lupus Therapeutics Market Outlook
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Treatment Type
11.2.2. By Route of Administration
11.2.3. By End User
11.2.4. By Country
11.3. South America: Country Analysis
11.3.1. Brazil Lupus Therapeutics Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Treatment Type
11.3.1.2.2. By Route of Administration
11.3.1.2.3. By End User
11.3.2. Argentina Lupus Therapeutics Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Treatment Type
11.3.2.2.2. By Route of Administration
11.3.2.2.3. By End User
11.3.3. Colombia Lupus Therapeutics Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Treatment Type
11.3.3.2.2. By Route of Administration
11.3.3.2.3. By End User
12. Middle East and Africa Lupus Therapeutics Market Outlook
12.1. Market Size & Forecast
12.1.1. By Value
12.2. Market Share & Forecast
12.2.1. By Treatment Type
12.2.2. By Route of Administration
12.2.3. By End User
12.2.4. By Country
12.3. MEA: Country Analysis
12.3.1. South Africa Lupus Therapeutics Market Outlook
12.3.1.1. Market Size & Forecast
12.3.1.1.1. By Value
12.3.1.2. Market Share & Forecast
12.3.1.2.1. By Treatment Type
12.3.1.2.2. By Route of Administration
12.3.1.2.3. By End User
12.3.2. Saudi Arabia Lupus Therapeutics Market Outlook
12.3.2.1. Market Size & Forecast
12.3.2.1.1. By Value
12.3.2.2. Market Share & Forecast
12.3.2.2.1. By Treatment Type
12.3.2.2.2. By Route of Administration
12.3.2.2.3. By End User
12.3.3. UAE Lupus Therapeutics Market Outlook
12.3.3.1. Market Size & Forecast
12.3.3.1.1. By Value
12.3.3.2. Market Share & Forecast
12.3.3.2.1. By Treatment Type
12.3.3.2.2. By Route of Administration
12.3.3.2.3. By End User
13. Market Dynamics
13.1. Drivers
13.2. Challenges
14. Market Trends & Developments
14.1. Product Launches
14.2. Mergers & Acquisitions
14.3. Recent Developments
15. Global Lupus Therapeutics Market: SWOT Analysis
